Reducing follow-up visits after breast cancer treatment
Part of Cancer, Skin clinical trials.
This study tests whether some patients who finished curative breast cancer treatment can safely have fewer follow-up appointments and scans. Researchers want to see if less frequent monitoring is safe for patients without any signs of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and completed curative (cancer-removing) treatment for primary breast cancer
- You are at least 18 years old and at least 24 months past your cancer treatment
- You have no signs of cancer coming back (no lumps, skin changes, or suspicious findings on recent scans)
- You speak, read, and write fluent English and can complete questionnaires
- You live in the Republic of Ireland and plan to continue your cancer follow-up care there
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether patients who have finished breast cancer treatment and are doing well can safely have fewer doctor visits and scans. Researchers want to see if reducing routine surveillance affects quality of life and health outcomes.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
This study monitors health problems that can happen over time in people with breast cancer while they receive usual treatments like hormone therapy, chemotherapy, and/or radiation. It may help researchers understand which extra symptoms or complications show up and when, to improve care and follow-up.
This study aims to help people with breast or lung cancer who worry about their cancer coming back. You will answer questionnaires about your fears, so the care team can better support you.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.